Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

ESMO Open

article

P. Heudel¹  S. Chabaud¹  D. Perol¹  A. Flechon¹  J. Fayette¹  P. Combemale¹  O. Tredan¹  F. Desseigne¹  C. de la Fouchardiere¹  H. Boyle¹  M. Perol¹  T. Bachelot¹  P. Cassier¹  V. Avrillon¹  C. Terret¹  A.-S. Michallet¹  E.-M. Neidhardt-Berard¹  E. Nicolas-Virelizier¹  A. Dufresne¹  A. Belhabri¹  M. Brahmi¹  L. Lebras¹  F. Nicolini¹  M. Sarabi¹  P. Rey¹  A. Bonneville-Levard¹  P. Rochefort¹  A.-M. Provensal¹  L. Eberst¹  S. Assaad¹  A. Swalduz¹  P. Saintigny¹  P. Toussaint¹  Y. Guillermin¹  M. Castets¹  C. Coutzac¹  P. Meeus¹  A. Dupré¹  T. Durand¹  H. Crochet¹  B. Fervers¹  F. Gomez¹  M. Rivoire¹  V. Gregoire¹  L. Claude¹  C. Chassagne-Clement¹  F. Pilleul¹  T. Mognetti¹  B. Russias¹  J.-L. Soubirou¹  C. Lasset¹  G. Chvetzoff¹  P. Mehlen¹  S. Beaupère¹  P. Zrounba¹  I. Ray-Coquard¹  J.-Y. Blay¹ 

[1] Centre Léon Bérard;Cancer Research Center of Lyon;Centre Léon Bérard & Université Claude Bernard;Unicancer

关键词: immunotherapy;    immune checkpoints;    second primary cancer;    second malignant neoplasia;   

DOI  :  10.1016/j.esmoop.2020.100044

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Background Second primary cancers (SPCs) are diagnosed in over 5% of patients after a first primary cancer (FPC). We explore here the impact of immune checkpoint inhibitors (ICIs) given for an FPC on the risk of SPC in different age groups, cancer types and treatments.Patients and methods The files of the 46 829 patients diagnosed with an FPC in the Centre Léon Bérard from 2013 to 2018 were analyzed. Structured data were extracted and electronic patient records were screened using a natural language processing tool, with validation using manual screening of 2818 files of patients. Univariate and multivariate analyses of the incidence of SPC according to patient characteristics and treatment were conducted.Results Among the 46 829 patients, 1830 (3.9%) had a diagnosis of SPC with a median interval of 11.1 months (range 0-78 months); 18 128 (38.7%) received cytotoxic chemotherapy (CC) and 1163 (2.5%) received ICIs for the treatment of the FPC in this period. SPCs were observed in 7/1163 (0.6%) patients who had received ICIs for their FPC versus 437/16 997 (2.6%) patients receiving CC and no ICIs for the FPC versus 1386/28 669 (4.8%) for patients receiving neither CC nor ICIs for the FPC. This reduction was observed at all ages and for all histotypes analyzed. Treatment with ICIs and/or CC for the FPC are associated with a reduced risk of SPC in multivariate analysis.Conclusion Immunotherapy with ICIs alone and in combination with CC was found to be associated with a reduced incidence of SPC for all ages and cancer types.

【 授权许可】

CC BY|CC BY-NC-ND